Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, Netherlands.
Curr Drug Targets. 2021;22(15):1738-1749. doi: 10.2174/1389450122666210120143450.
MicroRNAs (miRNAs) are non-coding RNAs containing around 22 nucleotides, which are expressed in vertebrates and plants. They act as posttranscriptional gene expression regulators, fine-tuning various biological processes in different cell types. There is emerging evidence on their role in different stages of atherosclerosis. In addition to regulating the inflammatory cells involved in atherosclerosis, miRNAs play fundamental roles in the pathophysiology of atherosclerosis, such as endothelial cell (EC) dysfunction, the aberrant function of the vascular smooth muscle cell (VSMC) and cholesterol metabolism. Moreover, miRNAs participate in several pathogenic pathways of atherosclerotic plaque development, including their effects on immune cell signaling receptors and lipid uptake. In this study, we review our current knowledge of the regulatory role of miRNAs in various pathogenic pathways underlying atherosclerosis development and also outline potential clinical applications of miRNAs in atherosclerosis.
微小 RNA(miRNA)是一类含有约 22 个核苷酸的非编码 RNA,在脊椎动物和植物中表达。它们作为转录后基因表达的调节剂,精细调节不同细胞类型中的各种生物学过程。越来越多的证据表明它们在动脉粥样硬化的不同阶段发挥作用。除了调节参与动脉粥样硬化的炎症细胞外,miRNA 还在动脉粥样硬化的病理生理学中发挥着基本作用,如内皮细胞(EC)功能障碍、血管平滑肌细胞(VSMC)的异常功能和胆固醇代谢。此外,miRNA 参与动脉粥样硬化斑块发展的几个致病途径,包括它们对免疫细胞信号受体和脂质摄取的影响。在这项研究中,我们回顾了 miRNA 在动脉粥样硬化发展的各种致病途径中调节作用的现有知识,并概述了 miRNA 在动脉粥样硬化中的潜在临床应用。